Cite
Ngolab J, Donohue M, Belsha A, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimers Dement (Amst). 2021;13(1):e12199doi: 10.1002/dad2.12199.
Ngolab, J., Donohue, M., Belsha, A., Salazar, J., Cohen, P., Jaiswal, S., Tan, V., Gessert, D., Korouri, S., Aggarwal, N. T., Alber, J., Johnson, K., Jicha, G., van Dyck, C., Lah, J., Salloway, S., Sperling, R. A., Aisen, P. S., Rafii, M. S., & Rissman, R. A. (2021). Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimer's & dementia (Amsterdam, Netherlands), 13(1), e12199. https://doi.org/10.1002/dad2.12199
Ngolab, Jennifer, et al. "Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial." Alzheimer's & dementia (Amsterdam, Netherlands) vol. 13,1 (2021): e12199. doi: https://doi.org/10.1002/dad2.12199
Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, Salloway S, Sperling RA, Aisen PS, Rafii MS, Rissman RA. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimers Dement (Amst). 2021 Aug 17;13(1):e12199. doi: 10.1002/dad2.12199. eCollection 2021. PMID: 34430703; PMCID: PMC8369843.
Copy
Download .nbib